<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is diagnosed in patients with <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> and/or pregnancy loss in the presence of persistent laboratory evidence for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnostic tests for the detection of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> include laboratory assays that detect anticardiolipin antibodies, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, and anti-Î²(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies </plain></SENT>
<SENT sid="2" pm="."><plain>Most studies on aPL have mainly focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL </plain></SENT>
<SENT sid="3" pm="."><plain>In this review we aimed to summarize and analyze the evidence published in the literature on the prevalence and the clinical significance of IgA aPL </plain></SENT>
</text></document>